Dapavo, P., M. Megna, and M. Talamonti. “Efficacy of Tildrakizumab 200 Mg for Treating Difficult-to-Treat Patient Populations With Moderate to Severe Plaque Psoriasis”. Dermatology Reports, Aug. 2024, doi:10.4081/dr.2024.9999.